作者
WM Michael Schuepbach, Lisa Tonder, Alfons Schnitzler, Paul Krack, Joern Rau, Andreas Hartmann, Thomas D Hälbig, Fanny Pineau, Andrea Falk, Laura Paschen, Stephen Paschen, Jens Volkmann, Haidar S Dafsari, Michael T Barbe, Gereon R Fink, Andrea Kühn, Andreas Kupsch, Gerd-H Schneider, Eric Seigneuret, Valerie Fraix, Andrea Kistner, P Patrick Chaynes, Fabienne Ory-Magne, Christine Brefel-Courbon, Jan Vesper, Lars Wojtecki, Stéphane Derrey, David Maltête, Philippe Damier, Pascal Derkinderen, Friederike Sixel-Döring, Claudia Trenkwalder, Alireza Gharabaghi, Tobias Wächter, Daniel Weiss, Marcus O Pinsker, Jean-Marie Regis, Tatiana Witjas, Stephane Thobois, Patrick Mertens, Karina Knudsen, Carmen Schade-Brittinger, Jean-Luc Houeto, Yves Agid, Marie Vidailhet, Lars Timmermann, Günther Deuschl, EARLYSTIM Study Group, EARLYSTIM study group
发表日期
2019/3/5
期刊
Neurology
卷号
92
期号
10
页码范围
e1109-e1120
出版商
Lippincott Williams & Wilkins
简介
Objective
To investigate predictors for improvement of disease-specific quality of life (QOL) after deep brain stimulation (DBS) of the subthalamic nucleus (STN) for Parkinson disease (PD) with early motor complications.
Methods
We performed a secondary analysis of data from the previously published EARLYSTIM study, a prospective randomized trial comparing STN-DBS (n = 124) to best medical treatment (n = 127) after 2 years follow-up with disease-specific QOL (39-item Parkinson's Disease Questionnaire summary index [PDQ-39-SI]) as the primary endpoint. Linear regression analyses of the baseline characteristics age, disease duration, duration of motor complications, and disease severity measured at baseline with the Unified Parkinson’s Disease Rating Scale (UPDRS) (UPDRS-III “off” and “on” medications, UPDRS-IV) were conducted to determine predictors of change in PDQ-39-SI.
Results
PDQ-39-SI at …
学术搜索中的文章
WMM Schuepbach, L Tonder, A Schnitzler, P Krack… - Neurology, 2019